[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4014/jmb.1508.08080

CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant Escherichia coli Harboring Extended-Spectrum β-Lactamases

Kim, Jun-Seob (Department of Genetic Engineering and Center for Human Interface Nano Technology, Sungkyunkwan University)
Cho, Da-Hyeong (Department of Genetic Engineering and Center for Human Interface Nano Technology, Sungkyunkwan University)
Park, Myeongseo (Department of Genetic Engineering and Center for Human Interface Nano Technology, Sungkyunkwan University)
Chung, Woo-Jae (Department of Genetic Engineering and Center for Human Interface Nano Technology, Sungkyunkwan University)
Shin, Dongwoo (Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine)
Ko, Kwan Soo (Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine)
Kweon, Dae-Hyuk (Department of Genetic Engineering and Center for Human Interface Nano Technology, Sungkyunkwan University)

Publication Information

Journal of Microbiology and Biotechnology / v.26, no.2, 2016 , pp. 394-401 More about this Journal

Abstract

Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9) system, a genome editing technology, was shown to be versatile in treating several antibiotic-resistant bacteria. In the present study, we applied the CRISPR/Cas9 technology to kill extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. ESBL bacteria are mostly multidrug resistant (MDR), and have plasmid-mediated antibiotic resistance genes that can be easily transferred to other members of the bacterial community by horizontal gene transfer. To restore sensitivity to antibiotics in these bacteria, we searched for a CRISPR/Cas9 target sequence that was conserved among >1,000 ESBL mutants. There was only one target sequence for each TEM- and SHV-type ESBL, with each of these sequences found in ~200 ESBL strains of each type. Furthermore, we showed that these target sequences can be exploited to re-sensitize MDR cells in which resistance is mediated by genes that are not the target of the CRISPR/Cas9 system, but by genes that are present on the same plasmid as target genes. We believe our Re-Sensitization to Antibiotics from Resistance (ReSAFR) technology, which enhances the practical value of the CRISPR/Cas9 system, will be an effective method of treatment against plasmid-carrying MDR bacteria.

Keywords

Extended-spectrum β-lactamases (ESBLs); multidrug resistance (MDR); re-sensitization; CRISPR/Cas9; antibiotic resistance;

Citations & Related Records

Reference

1	Abraham EP, Chain E. 1940. An enzyme from bacteria able to destroy penicillin. Rev. Infect. Dis. 10: 677-678.
2	Bhaya D, Davison M, Barrangou R. 2011. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu. Rev. Genet. 45: 273-297. DOI
3	Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. 2014. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32: 1146-1150. DOI
4	Citorik RJ, Mimee M, Lu TK. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32: 1141-1145. DOI
5	Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823. DOI
6	Fleming A. 1929. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ. Br. J. Exp. Pathol. 10: 226-236.
7	Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. 2013. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31: 233-239. DOI
8	Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821. DOI
9	Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA. 2009. Characterization and sequence analysis of extended-spectrum-b-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob. Agents Chemother. 53: 465-475. DOI
10	Paterson DL. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6: 460-463. DOI
11	Kaur M, Aggarwal A. 2013. Occurrence of the CTX-M, SHV and the TEM genes among the extended spectrum beta-lactamase producing isolates of Enterobacteriaceae in a tertiary care hospital of North India. J. Clin. Diagn. Res. 7: 642-645.
12	Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11: 315-317. DOI
13	Lew W, Pai M, Oxlade O, Martin D, Menzies D. 2008. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med. 149: 123-134. DOI
14	Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18: 657-686. DOI
15	Rawat D, Nair D. 2010. Extended-spectrum beta-lactamases in gram-negative bacteria. J. Global Infect. Dis. 2: 263-274. DOI
16	Sanders CC, Sanders WE Jr. 1979. Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob. Agents Chemother. 15: 792-797. DOI
17	Tissera S, Lee SM. 2013. Isolation of extended spectrum beta-lactamase (ESBL) producing bacteria from urban surface waters in Malaysia. Malays. J. Med. Sci. 20: 14-22.
18	van der Oost J, Westra ER, Jackson RN, Wiedenheft B. 2014. Unravelling the structural and mechanistic basis of CRISPR-Cas systems. Nat. Rev. Microbiol. 12: 479-492. DOI
19	Wiedenheft B, Sternberg SH, Doudna JA. 2012. RNA-guided genetic silencing systems in bacteria and archaea. Nature 482: 331-338. DOI
20	Walsh CT, Wencewicz TA. 2014. Prospects for new antibiotics: a molecule-centered perspective. J. Antibiot. 67: 7-22. DOI
21	Wise R. 2002. Antimicrobial resistance: priorities for action. J. Antimicrob. Chemother. 49: 585-586. DOI
22	Woodford N, Livermore DM. 2009. Infections caused by gram-positive bacteria: a review of the global challenge. J. Infect. 59 (Suppl 1): S4-S16. DOI
23	Yosef I, Manor M, Kiro R, Qimron U. 2015. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA 112: 7267-7272. DOI
24	Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66: 571-591. DOI

Reference

6	(2016) mBio Predatory Bacteria Attenuate <I>Klebsiella pneumoniae</I> Burden in Rat Lungs / 7 (6) , e01847-16
None	(2016) Microbial cell factories A versatile one-step CRISPR-Cas9 based approach to plasmid-curing / 16 (None) , 135
6	(2018) PLoS pathogens CRISPR-Cas antimicrobials: Challenges and future prospects / 14 (6) , e1006990
4	(2019) Journal of clinical microbiology CRISPR-Cas Biology and Its Application to Infectious Diseases / 57 (4) , e01307-18
1	(2019) Annals of clinical microbiology and antimicrobials CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens / 18 (1) , 21
1	(2019) Journal of animal science and biotechnology Application of new biotechnologies for improvements in swine nutrition and pork production / 10 (1) , 28
None	(2016) Frontiers in microbiology Targeting Plasmids to Limit Acquisition and Transmission of Antimicrobial Resistance / 11 (None) , 761
8	(2016) Infection and immunity Innate Effector Systems in Primary Human Macrophages Sensitize Multidrug-Resistant <I>Klebsiella pneumoniae</I> to Antibiotics / 88 (8) , e00186-20
8	(2016) IUBMB life <SMALL>CRISPR</SMALL> /Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity / 72 (8) , 1603
9	(2016) Antimicrobial agents and chemotherapy CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant <I>Enterobacteriaceae</I> / 64 (9) , e00843-20
None	(2016) Frontiers in microbiology Enlarging the Toolbox Against Antimicrobial Resistance: Aptamers and CRISPR-Cas / 12 (None) , 606360
None	(2016) Frontiers in microbiology Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance / 12 (None) , 716064
2	(2016) Microorganisms The History of Colistin Resistance Mechanisms in Bacteria: Progress and Challenges / 9 (2) , 442
3	(2016) Antimicrobial agents and chemotherapy Interplay among Different Fosfomycin Resistance Mechanisms in <I>Klebsiella pneumoniae</I> / 65 (3) , e01911-20
3	(2016) Antibiotics Use of Bacteriophage Amended with CRISPR-Cas Systems to Combat Antimicrobial Resistance in the Bacterial Foodborne Pathogen Listeria monocytogenes / 10 (3) , 308
3	(2021) Pharmaceutics Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles / 13 (3) , 352
7	(2016) International journal of molecular sciences Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives / 22 (7) , 3327
4	(2016) ACS Synthetic biology Genetically Intact Bioengineered Spores of <I>Bacillus</I><I>subtilis</I> / 10 (4) , 778
5	(2016) Antibiotics Unveiling the Impact of Antibiotics and Alternative Methods for Animal Husbandry: A Review / 10 (5) , 578
7	(2016) Antibiotics CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies / 10 (7) , 756
1	(2016) Journal of nanobiotechnology Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections / 19 (1) , 401